Aligos Therapeutics Appoints Laura Kavanaugh as Vice President, Head of Legal
Aligos Therapeutics (Nasdaq: ALGS) has appointed Laura Kavanaugh, JD as Vice President, Head of Legal, effective immediately. Kavanaugh brings over 25 years of experience in the biotechnology and pharmaceutical industries. She most recently served as Vice President, Corporate Law & Privacy Officer at Codexis. Her previous roles include being an independent legal consultant for companies like Genentech and Elan Pharmaceuticals, and serving as Practice Group Leader for BioOncology Development Law at Genentech.
The appointment was announced by Lesley Ann Calhoun, Executive Vice President, Chief Operating Officer, and Chief Financial Officer at Aligos, who emphasized Kavanaugh's extensive knowledge and broad expertise in legal matters. Kavanaugh holds a BA from UC Berkeley and a JD from Santa Clara University Law School.
Aligos Therapeutics (Nasdaq: ALGS) ha nominato Laura Kavanaugh, JD come Vicepresidente e Responsabile dell'Ufficio Legale, con effetto immediato. Kavanaugh vanta oltre 25 anni di esperienza nei settori biotecnologico e farmaceutico. Recentemente ha ricoperto il ruolo di Vicepresidente, Corporate Law & Privacy Officer presso Codexis. In precedenza è stata consulente legale indipendente per aziende come Genentech ed Elan Pharmaceuticals, oltre a dirigere il gruppo di pratica per il diritto dello sviluppo BioOncologico presso Genentech.
La nomina è stata annunciata da Lesley Ann Calhoun, Vicepresidente Esecutiva, Chief Operating Officer e Chief Financial Officer di Aligos, che ha sottolineato l'ampia conoscenza e competenza legale di Kavanaugh. Kavanaugh ha conseguito una laurea presso UC Berkeley e un JD presso la Santa Clara University Law School.
Aligos Therapeutics (Nasdaq: ALGS) ha nombrado a Laura Kavanaugh, JD como Vicepresidenta y Jefa del Departamento Legal, con efecto inmediato. Kavanaugh cuenta con más de 25 años de experiencia en las industrias biotecnológica y farmacéutica. Recientemente se desempeñó como Vicepresidenta de Derecho Corporativo y Oficial de Privacidad en Codexis. Anteriormente, fue consultora legal independiente para empresas como Genentech y Elan Pharmaceuticals, y lideró el grupo de práctica de Derecho de Desarrollo BioOncológico en Genentech.
El nombramiento fue anunciado por Lesley Ann Calhoun, Vicepresidenta Ejecutiva, Directora de Operaciones y Directora Financiera de Aligos, quien destacó el amplio conocimiento y experiencia legal de Kavanaugh. Kavanaugh posee una licenciatura de UC Berkeley y un JD de la Facultad de Derecho de la Universidad de Santa Clara.
Aligos Therapeutics (나스닥: ALGS)는 Laura Kavanaugh, JD를 즉시 효력을 발휘하는 법무부 부사장 겸 책임자로 임명했습니다. Kavanaugh는 생명공학 및 제약 산업에서 25년 이상의 경험을 보유하고 있습니다. 최근에는 Codexis에서 기업법 및 개인정보 보호 책임자 부사장으로 근무했습니다. 이전에는 Genentech와 Elan Pharmaceuticals와 같은 회사의 독립 법률 컨설턴트로 활동했으며, Genentech에서 바이오종양학 개발 법률 실무 그룹 리더를 역임했습니다.
이 임명은 Aligos의 최고운영책임자 겸 최고재무책임자인 Lesley Ann Calhoun 부사장이 발표했으며, Kavanaugh의 폭넓은 법률 지식과 전문성을 강조했습니다. Kavanaugh는 UC 버클리에서 학사 학위를, 산타클라라 대학교 법대에서 법학 박사(JD)를 취득했습니다.
Aligos Therapeutics (Nasdaq : ALGS) a nommé Laura Kavanaugh, JD au poste de Vice-Présidente et Responsable Juridique, avec effet immédiat. Kavanaugh apporte plus de 25 ans d'expérience dans les industries biotechnologique et pharmaceutique. Elle a récemment occupé le poste de Vice-Présidente, Droit des Sociétés et Responsable de la Protection de la Vie Privée chez Codexis. Ses expériences antérieures incluent le rôle de consultante juridique indépendante pour des sociétés telles que Genentech et Elan Pharmaceuticals, ainsi que la direction du groupe de pratique en droit du développement BioOncologique chez Genentech.
La nomination a été annoncée par Lesley Ann Calhoun, Vice-Présidente Exécutive, Directrice des Opérations et Directrice Financière chez Aligos, qui a souligné la vaste connaissance et l'expertise juridique de Kavanaugh. Kavanaugh est titulaire d'un BA de l'UC Berkeley et d'un JD de la faculté de droit de l'Université de Santa Clara.
Aligos Therapeutics (Nasdaq: ALGS) hat Laura Kavanaugh, JD mit sofortiger Wirkung zur Vizepräsidentin und Leiterin der Rechtsabteilung ernannt. Kavanaugh verfügt über mehr als 25 Jahre Erfahrung in der Biotechnologie- und Pharmaindustrie. Zuletzt war sie Vice President für Unternehmensrecht und Datenschutzbeauftragte bei Codexis. Zuvor arbeitete sie als unabhängige Rechtsberaterin für Unternehmen wie Genentech und Elan Pharmaceuticals und leitete die Praxisgruppe für Bioonkologie-Entwicklungsrecht bei Genentech.
Die Ernennung wurde von Lesley Ann Calhoun, Executive Vice President, Chief Operating Officer und Chief Financial Officer bei Aligos, bekannt gegeben, die Kavanaughs umfassendes Wissen und ihre breite Expertise im Rechtsbereich hervorhob. Kavanaugh hat einen BA von der UC Berkeley und einen JD von der Santa Clara University Law School.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Laura Kavanaugh, JD as Vice President, Head of Legal, effective immediately.
“I am thrilled to welcome Laura to the Aligos team,” said Lesley Ann Calhoun, Executive Vice President, Chief Operating Officer, and Chief Financial Officer at Aligos. “Laura brings with her a wealth of experience in all legal aspects from both biotech companies as well as large pharmaceutical firms. Her extensive knowledge and broad expertise will undoubtedly provide invaluable leadership and oversight on all legal matters.”
“I am honored to join the dynamic team at Aligos,” stated Laura Kavanaugh, Vice President, Head of Legal at Aligos. “I look forward to working with my new colleagues to navigate the complex legal landscape to drive forward our mission of improving patient outcomes.”
Ms. Kavanaugh joins Aligos with more than 25 years of experience as an attorney and leader in the biotechnology and pharmaceutical industries. Most recently, she served as Vice President, Corporate Law & Privacy Officer at Codexis. Previously, Ms. Kavanaugh was an independent legal consultant for clients including Genentech, Elan Pharmaceuticals, Allakos, ZS Pharma, and Principia. She also held roles of increasing responsibility at Elan Pharmaceuticals and at Genentech, where she ultimately served as Practice Group Leader, BioOncology Development Law. Her career began as an associate at a prominent Silicon Valley law firm. Ms. Kavanaugh earned a BA from the University of California, Berkley and a JD from Santa Clara University Law School.
About Aligos
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for high unmet medical needs such as chronic hepatitis B virus infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses.
For more information, please visit www.aligos.com or follow us on LinkedIn or X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements regarding Aligos’ financial results and performance as well as research and development activities, including regulatory status and the timing of announcements and updates relating to our regulatory filings and clinical trials. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, and other matters that could affect the sufficiency of Aligos’ capital resources to fund operations. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 6, 2025 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.
Aligos Therapeutics
Contact
Jordyn Tarazi
Vice President, Investor Relations & Corporate Communications
+1 (650) 910-0427
jtarazi@aligos.com
Media Contact
Inizio Evoke
Jake Robison
Vice President
Jake.Robison@inzioevoke.com
FAQ
Who is Laura Kavanaugh and what is her new role at Aligos Therapeutics (ALGS)?
What was Laura Kavanaugh's previous position before joining Aligos Therapeutics (ALGS)?
What is Laura Kavanaugh's educational background?
What companies has Laura Kavanaugh worked with in her career?
